Market Analysis - Cancer Nursing 2017
Conference Series LLC is overwhelmed to announce the commencement of "25th Cancer Nursing & Nurse Practitioners Conference" on July 17-18, 2017 in Lisbon, Portugal.
The upcoming conference will be organized around the theme "Caring is the Essence of Cancer Nursing".
Scope and Importance:
Nursing in cancer care focuses on patient assessment, education, symptom management, and supportive care. In medical oncology they play an integral role in the administration of antineoplastic agents and are responsible for safe drug handling; evaluation of laboratory data; calculation of drug dosages on the basis of body surface area; insertion of intravenous lines or accessing central venous devices; continuous and time intensive monitoring to address potential adverse reactions or drug interactions; and screening patients for inclusion in available research trials or protocols. In the radiation oncology arena the nurses need to have an understanding of radiobiology and radiation physics. They are also responsible for extensive symptom management, patient education and the submission process for clinical trials or research protocols.
Why Lisbon, Portugal?
Lisbon is the capital and the largest city of Portugal, with a population of 552,700 within its administrative limits in an area of 100.05 km². Its urban area extends beyond the city’s administrative limits with a population of around 2.7 million people, being the 11th-most populous urban area in the European Union. About 2.8 million people live in the Lisbon Metropolitan Area (which represents approximately 27% of the country’s population).
Lisbon is recognized as a global city because of its importance in finance, commerce, media, entertainment, arts, international trade, education and tourism. It is one of the major economic centers on the continent, with a growing financial sector and one of the largest container ports on Europe's Atlantic coast. Lisbon Portela Airport serves over 20 million passengers annually, as of 2015, and the motorway network and the high-speed rail system of Alfa Pendular link the main cities of Portugal. The city is the 7th-most-visited city in Southern Europe. The city occupies 32nd place of highest gross earnings in the world. Most of the headquarters of multinationals in the country are located in the Lisbon area. It is also the political center of the country, as its seat of Government and residence of the Head of State.
The city is crossed by historical boulevards and monuments along the main thoroughfares, particularly in the upper districts; notable among these are the Avenue of Liberty, Avenida Fontes Pereira de Melo, Avenida Almirante Reis and Avenue of the Republic. The Pombaline Lower Town area covers about 235,620 square meters of central Lisbon. The Alfama is the oldest district of Lisbon, spreading on the slope between the Sao Jorge Castle and the Tejo River. The district contains many important historical attractions, as well as an abundance of Fado bars and restaurants. Bairro Alto is an area of central Lisbon that functions as a residential, shopping and entertainment district; it is the centre of the Portuguese capital's nightlife, attracting hipster youth and members of various music subcultures. Lisbon lacks the architecture and monuments of many other historic European capitals in large part due to the 1755 Lisbon earthquake, which destroyed most of Lisbon's buildings, including famous palaces and libraries, as well as most examples of Portugal's distinctive 16th-century Manueline architecture.
Cancer Cell Biology
Carcinogenesis and Mutagenesis
Cancer Trends and Opportunities
World Cancer Market
General Issues in Cancer Nursing
Cancer Therapy and Treatment
Complementary and Alternative Medicine
Cancer Pain Management
Supportive Care Services
Cancer Therapeutics and Metabolomics
Cancer Immunotherapy & Stem Cell Therapy
Cancer Basic and Applied Research
Companion Diagnostics in Oncology
Breast Cancer Nursing
Surgical Oncology Nursing
- Cancer Researchers
- Cancer research Faculty
- Medical Colleges
- Cancer Associations and Societies
- Nursing Faculty
- Business Entrepreneurs
- Medical Devices Manufacturing Companies
- Pharmaceutical Companies
- Research Scholars
- Biomedical Companies
- Diagnostics Companies
Why to attend???
With members from around the world focused on learning about Oncology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Oncology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new ways of treatment & care, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Oncology are hallmarks of this conference.
A Unique Opportunity for Advertisers and Sponsors at this International event:
Market Analysis Report
Advances in understanding of the immune system are changing the way oncologists treat cancer. In recent years, researchers have increasingly looked to harnessing the patient's immune system in the management of difficult to treat cancers. While such an approach was once felt to be unattainable, a better understanding of how the adaptive immune system works has allowed the field of immuno-oncology to move to the clinic with increasing success. This study's objective was to assess practicing oncologists' familiarity with, and understanding of, immuno-oncology concepts that will play an important role in the care of patients with metastatic cancer such as those with lung cancer. A total of 469 of oncologist have participated in the surveys. Overall, oncologists reported a lack of familiarity and need for additional education in the areas of immunology as well as implications for immuno-oncology agents. Less than 15% of oncologists reported being very familiar with the immune system while 72% of learners indicated a need for additional education on adaptive immune responses. In addition, only 7% and11% of oncologists reported being very familiar with the concepts of immune escape and check points, respectively. Over 60% of oncologists reported little familiarity with emerging immunotherapies for the treatment of metastatic solid tumors, and a majority did not have a firm understanding of how to assess a patient's response According to the Asian healthcare industry is witnessing a paradigm shift, skewed towards point-of-care diagnostics, cost-effective personalized medicine, and treatment modalities, which not only offers efficient early diagnosis, but also treats cancer conditions in order to moderate the healthcare cost and disease liability. Cancer/Tumor profiling is one such technology with the exact potential to transform cancer/tumor diagnostics and therapeutics in the healthcare industry.
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumor in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumor if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumor in men, has an increasingly favorable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
This market research report evaluates the Asian market of cancer/tumor profiling by geography, applications, technologies, and section types. Additionally, the requirements market is divided into five segments, namely Personalized Medicine, Biomarker Discovery, Diagnostics, Prognosis and Research Submissions; the technologies section is divided into five segments, namely Next-Generation Sequencing, Quantitative PCR, FISH/CISH, Immunohistochemistry, and Microarray; and finally, the segment types is partitioned into four parts, namely Genomics, Metabolomics, Proteomics, and Epigenetics. Of the above-mentioned application fragments, modified medicine is the largest revenue segment and NGS is the potential revenue yielding technology.
The cancer/tumor describing market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018.
The global market for cancer/tumor reporting is expected to grow, backed by technological advancements, investments, and huge funds. The market is endorsing a trend towards the development of personalized medicine and point-of-care diagnostic tests for cancer. Additionally, the demand for safe and cost-effective drugs for the treatment of cancer (which can be fulfilled by cancer/tumor profiling therapeutics), will fuel the market growth. However, the market will also experience improvements in biomarker discovery and prognosis areas during the forecast period.
Asia-Pacific is the largest hub for cancer/tumor profiling market, accounting for the largest share, followed by China and Australia. Asia-Pacific and Europe are expected to grow at a steady pace. However, the North America market and few countries from the ROW region are expected to witness a boost in demand and are poised to register maximum growth over the next five years, owing to high incidence of cancers, affected population, and the increased purchasing power of patients.